Davide F Robbiani
Overview
Explore the profile of Davide F Robbiani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
9676
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Muri J, Cecchinato V, Cavalli A, Shanbhag A, Matkovic M, Biggiogero M, et al.
Nat Immunol
. 2023 Mar;
24(4):604-611.
PMID: 36879067
Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse symptoms, which can persist for months. While antiviral antibodies are protective, those targeting interferons and other immune factors are...
12.
Bianchini F, Crivelli V, Abernathy M, Guerra C, Palus M, Muri J, et al.
Sci Immunol
. 2023 Jan;
8(81):eade0958.
PMID: 36701425
Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued development of immunotherapies and vaccine immunogens resilient to viral evolution...
13.
Bianchini F, Crivelli V, Abernathy M, Guerra C, Palus M, Muri J, et al.
bioRxiv
. 2022 Dec;
PMID: 36482967
One Sentence Summary: Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery.
14.
Muri J, Cecchinato V, Cavalli A, Shanbhag A, Matkovic M, Biggiogero M, et al.
bioRxiv
. 2022 Jun;
PMID: 35664993
One-sentence Summary: Naturally arising anti-chemokine antibodies associate with favorable COVID-19 and predict lack of long COVID.
15.
De Gasparo R, Pedotti M, Simonelli L, Nickl P, Muecksch F, Cassaniti I, et al.
Nature
. 2021 Aug;
597(7874):E2.
PMID: 34345019
No abstract available.
16.
Robbiani D, Ruzek D
J Exp Med
. 2021 Jul;
218(9).
PMID: 34319348
The NS1 protein of flaviviruses is taking center stage. Recent work has made it an attractive target for development of vaccines and immunotherapeutics. Cavazzoni and colleagues (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210580)...
17.
Greaney A, Starr T, Barnes C, Weisblum Y, Schmidt F, Caskey M, et al.
Nat Commun
. 2021 Jul;
12(1):4196.
PMID: 34234131
Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals previously infected with SARS-CoV-2, but the relative contributions of these different antibody classes to the polyclonal response remains...
18.
Agudelo M, Palus M, Keeffe J, Bianchini F, Svoboda P, Salat J, et al.
J Exp Med
. 2021 Apr;
218(5).
PMID: 33831141
Tick-borne encephalitis virus (TBEV) is an emerging human pathogen that causes potentially fatal disease with no specific treatment. Mouse monoclonal antibodies are protective against TBEV, but little is known about...
19.
De Gasparo R, Pedotti M, Simonelli L, Nickl P, Muecksch F, Cassaniti I, et al.
Nature
. 2021 Mar;
593(7859):424-428.
PMID: 33767445
Neutralizing antibodies that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein are among the most promising approaches against COVID-19. A bispecific IgG1-like molecule (CoV-X2) has been developed on...
20.
Greaney A, Starr T, Barnes C, Weisblum Y, Schmidt F, Caskey M, et al.
bioRxiv
. 2021 Mar;
PMID: 33758856
Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals previously infected with SARS-CoV-2, but the relative contributions of these different antibody classes to the polyclonal response remains...